PTGX Protagonist Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTGX

Price (delayed)

$26.09

Market cap

$1.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.39

Enterprise value

$1.33B

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 ...

Highlights
PTGX's gross profit has soared by 126% YoY
Protagonist Therapeutics's revenue has surged by 126% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protagonist-inc.com
Peers: OMER OMGA

Key stats

What are the main financial stats of PTGX
Market
Shares outstanding
58.27M
Market cap
$1.52B
Enterprise value
$1.33B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.47
Price to sales (P/S)
24.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.25
Earnings
Revenue
$60M
EBIT
-$78.96M
EBITDA
-$75.64M
Free cash flow
-$70.85M
Per share
EPS
-$1.39
Free cash flow per share
-$1.25
Book value per share
$5.84
Revenue per share
$1.06
TBVPS
$6.31
Balance sheet
Total assets
$357.95M
Total liabilities
$21.27M
Debt
$1.14M
Equity
$336.68M
Working capital
$334.3M
Liquidity
Debt to equity
0
Current ratio
16.71
Quick ratio
16.53
Net debt/EBITDA
2.45
Margins
EBITDA margin
-126.1%
Gross margin
100%
Net margin
-131.6%
Operating margin
-156.1%
Efficiency
Return on assets
-25.3%
Return on equity
-27.5%
Return on invested capital
-83.6%
Return on capital employed
-23.5%
Return on sales
-131.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTGX stock price

How has the Protagonist Therapeutics stock price performed over time
Intraday
2.15%
1 week
3.74%
1 month
-7.05%
1 year
6.71%
YTD
13.78%
QTD
-9.82%

Financial performance

How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$60M
Gross profit
$60M
Operating income
-$93.65M
Net income
-$78.96M
Gross margin
100%
Net margin
-131.6%
PTGX's gross profit has soared by 126% YoY
Protagonist Therapeutics's revenue has surged by 126% YoY
The net margin has surged by 73% year-on-year
The operating margin has soared by 68% YoY

Growth

What is Protagonist Therapeutics's growth rate over time

Valuation

What is Protagonist Therapeutics stock price valuation
P/E
N/A
P/B
4.47
P/S
24.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.25
Protagonist Therapeutics's EPS has increased by 47% QoQ and by 47% YoY
The equity has soared by 56% YoY and by 11% from the previous quarter
The P/B is 25% more than the 5-year quarterly average of 3.5 but 2.7% less than the last 4 quarters average of 4.5
Protagonist Therapeutics's revenue has surged by 126% YoY
The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 173.0

Efficiency

How efficient is Protagonist Therapeutics business performance
Protagonist Therapeutics's return on sales has surged by 73% YoY
The ROIC has soared by 52% from the previous quarter and by 8% YoY
The company's return on equity rose by 50% QoQ and by 44% YoY
PTGX's ROA is up by 49% since the previous quarter and by 41% year-on-year

Dividends

What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTGX.

Financial health

How did Protagonist Therapeutics financials performed over time
The quick ratio has soared by 117% YoY and by 44% from the previous quarter
The current ratio has surged by 114% year-on-year and by 43% since the previous quarter
The debt is 100% smaller than the equity
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
The debt has dropped by 69% year-on-year and by 37% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.